Research Study

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)
Principal Investigator 
Sasha Smiljanic

Overview

Body Locations and Systems 
Melanoma
Disorders and Conditions 
Melanoma
ClinicalTrials.gov# 
NCT02752074
Status 
Recruiting
Study Start/End 
Sep 6, 2016 to May 3, 2021
Locations 
Lions Gate Hospital
Name/Title 
Valla Sahraei, Research Coordinator
Phone 
604-988-3131 ext:4934
Email Address 
valla.sahraei@vch.ca
Purpose of Study 

The purpose of the study is to assess the efficacy, safety, and tolerability when combining pembrolizumab with epacadostat or placebo in subjects with unresectable or metastatic melanoma.

Eligibility 

Visit ClinicalTrials.gov for more information. 

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.